Key Takeaways
- Q2 adjusted EPS of $7.45 surpassed Wall Street’s $6.21 forecast by $1.24
- Quarterly revenue of $49.8 billion exceeded the $48.63 billion projection
- Operating margin contracted to 3.5% from 4.9% in the prior-year period, alarming the market
- Shares plummeted over 9% in premarket activity despite exceeding expectations
- Company increased full-year adjusted EPS outlook to a minimum of $27.00 from $26.75
Elevance Health delivered a strong Q2 performance that exceeded Wall Street’s projections on Wednesday, yet shares tumbled as market participants focused on deteriorating profitability metrics.
Shares of ELV plunged over 9% during premarket hours following the earnings release. Prior to the report, the stock had surged nearly 22% year-to-date in 2026, finishing Monday’s session at $426.79.
The health insurer reported adjusted earnings of $7.45 per share, handily surpassing the Street’s consensus forecast of $6.21 by a substantial $1.24. Quarterly revenue totaled $49.8 billion, representing a modest 0.8% annual increase and topping the anticipated $48.63 billion.
Despite the impressive topline performance, market sentiment turned negative. The company’s operating margin deteriorated to 3.5% from 4.9% during the comparable quarter last year. Similarly, the adjusted operating margin declined from 5.0% to 3.6%.
Within the company’s flagship Health Benefits division, the margin compression was even more pronounced. This segment saw operating margin fall to 2.1%, down from 3.8% in the year-ago period.
The benefit expense ratio climbed 80 basis points year-over-year, reaching 89.7%. Higher medical expenses across government-sponsored programs fueled this expansion, though stronger results in Individual ACA plans provided partial relief.
Management Raises Outlook
Elevance boosted its full-year adjusted EPS projection to a minimum of $27.00, an increase from the prior floor of $26.75. This updated guidance slightly exceeds the analyst consensus estimate of $26.91. The company also elevated its operating cash flow forecast to at least $6.0 billion.
This represents the second upward revision to guidance in recent months. Management previously raised its outlook in April and confirmed it again in June.
CEO Gail Boudreaux commented that the results “exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio.”
Membership Headwinds
Medical membership totaled approximately 44.9 million members at quarter-end on June 30, 2026, representing a sequential decrease of 469,000 members. This reduction stemmed from a commercial fee-based customer migration and anticipated attrition across Individual ACA and Medicaid plans.
The Health Benefits division generated $42.7 billion in revenue, marking a 3% year-over-year gain. Meanwhile, the Carelon segment posted revenue growth of 6%, reaching $19.2 billion.
Wall Street analysts maintained an optimistic stance ahead of the quarterly report. TD Cowen analyst Ryan Langston increased his price objective on Elevance from $400 to $465 on Tuesday. Cantor Fitzgerald similarly raised its target from $400 to $450.
Medicaid profitability remains under close scrutiny. CFO Mark Kaye indicated at a Goldman Sachs healthcare conference in June that expenses in this segment remained elevated, with full-year margin expectations hovering around -1.75%.
UBS analyst A.J. Rice characterized that projection as “conservative,” indicating potential upside opportunities.
Elevance’s earnings release comes one day ahead of UnitedHealth Group, the industry’s dominant player, which is scheduled to announce results Thursday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
